title: Translating Neurogenomics Into New Medicines.
abstract: Brain disorders remain one of the defining challenges of modern medicine and among the most poorly served with new therapeutics. Advances in human neurogenetics have begun to shed light on the genomic architecture of complex diseases of mood, cognition, brain development, and neurodegeneration. From genome-wide association studies to rare variants, these findings hold promise for defining the pathogenesis of brain disorders that have resisted simple molecular description. However, the path from genetics to new medicines is far from clear and can take decades, even for the most well-understood genetic disorders. In this review, we define three challenges for the field of neurogenetics that we believe must be addressed to translate human genetics efficiently into new therapeutics for brain disorders.
authors.affiliation: PharmaTherapeutics Clinical Research, Worldwide Research and Development, Pfizer Inc., Cambridge, Massachusetts.
authors.forename: Jens R
authors.initials: JR
authors.lastname: Wendland
authors.affiliation: Neuroscience Research Unit, Worldwide Research and Development, Pfizer Inc., Cambridge, Massachusetts. Electronic address: michael.ehlers@pfizer.com.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Ehlers
mesh_terms: D001927:Brain Diseases / Q000235:genetics* / Q000628:therapy*; D023281:Genomics / Q000379:methods*; D006801:Humans; D057285:Precision Medicine / Q000379:methods; D057170:Translational Research, Biomedical / Q000379:methods*
keywords: Brain disorders; Circuits; GWAS; Genes; Genomics; Human genetics; Psychiatry; Translational medicine